Subscribe to RSS
Please copy the URL and add it into your RSS Feed Reader.
https://www.thieme-connect.de/rss/thieme/en/10.1055-s-00000075.xml
Download PDF
Semin Respir Crit Care Med 2006; 27(3): 241-261
DOI: 10.1055/s-2006-945528
DOI: 10.1055/s-2006-945528
Intensive Management of Hepatic Failure
Further Information
Publication History
Publication Date:
21 June 2006 (online)
ABSTRACT
A substantial number of patients with liver failure are admitted to the intensive care unit; thus a thorough understanding of the prevention and treatment of complications in such patients is imperative. The management of liver failure is demanding and often involves the combined efforts of many specialists. Critically ill patients with hepatic failure encompass a broad spectrum of disease, ranging from acute liver failure in a patient with no prior history of liver disease, to acute on chronic liver failure. The initial assessment and management of acute liver failure are reviewed with an emphasis on the prevention and treatment of brain edema in the pretransplant setting. The current treatment of complications resulting from decompensated chronic liver disease such as portal hypertensive bleeding; infection, renal failure, and hepatic encephalopathy are then discussed.
KEYWORDS
Liver failure - cerebral edema - portal hypertension - management
REFERENCES
- 1 Trey C, Lipworth L, Davidson C S. Halothane and liver damage. N Engl J Med. 1969; 280 562-563
- 2 Trey C, Davidson C S. The management of fulminant hepatic failure. Prog Liver Dis. 1970; 3 282-298
- 3 Bernal W, Wendon J. Liver transplantation in adults with acute liver failure. J Hepatol. 2004; 40 192-197
- 4 Blei A T. Medical therapy of brain edema in fulminant hepatic failure. Hepatology. 2000; 32 666-669
- 5 Mas A, Rodes J. Fulminant hepatic failure. Lancet. 1997; 349 1081-1085
- 6 Larsen F S, Wendon J. Brain edema in liver failure: basic physiologic principles and management. Liver Transpl. 2002; 8 983-989
- 7 O'Grady J G, Alexander G J, Hayllar K M, Williams R. Early indicators of prognosis in fulminant hepatic failure. Gastroenterology. 1989; 97 439-446
- 8 Izumi S, Langley P G, Wendon J et al.. Coagulation factor V levels as a prognostic indicator in fulminant hepatic failure. Hepatology. 1996; 23 1507-1511
- 9 Pereira L M, Langley P G, Hayllar K M, Tredger J M, Williams R. Coagulation factor V and VIII/V ratio as predictors of outcome in paracetamol induced fulminant hepatic failure: relation to other prognostic indicators. Gut. 1992; 33 98-102
- 10 Lee W M. Acute liver failure in the United States. Semin Liver Dis. 2003; 23 217-226
- 11 Seeff L B, Cuccherini B A, Zimmerman H J, Adler E, Benjamin S B. Acetaminophen hepatotoxicity in alcoholics: a therapeutic misadventure. Ann Intern Med. 1986; 104 399-404
- 12 Ostapowicz G, Fontana R J, Schiodt F V et al.. Results of a prospective study of acute liver failure at 17 tertiary care centers in the United States. Ann Intern Med. 2002; 137 947-954
- 13 Makin A J, Wendon J, Williams R. A 7-year experience of severe acetaminophen-induced hepatotoxicity (1987-1993). Gastroenterology. 1995; 109 1907-1916
- 14 Zimmerman H J, Maddrey W C. Acetaminophen (paracetamol) hepatotoxicity with regular intake of alcohol: analysis of instances of therapeutic misadventure. Hepatology. 1995; 22 767-773
- 15 Schiodt F V, Rochling F A, Casey D L, Lee W M. Acetaminophen toxicity in an urban county hospital. N Engl J Med. 1997; 337 1112-1117
- 16 McClain C J, Kromhout J P, Peterson F J, Holtzman J L. Potentiation of acetaminophen hepatotoxicity by alcohol. JAMA. 1980; 244 251-253
- 17 Murphy R, Swartz R, Watkins P B. Severe acetaminophen toxicity in a patient receiving isoniazid. Ann Intern Med. 1990; 113 799-800
- 18 Prescott L F, Critchley J A. The treatment of acetaminophen poisoning. Annu Rev Pharmacol Toxicol. 1983; 23 87-101
- 19 Lee W M. Acetaminophen and the U.S. Acute Liver Failure Study Group: lowering the risks of hepatic failure. Hepatology. 2004; 40 6-9
- 20 Harrison P M, Keays R, Bray G P, Alexander G J, Williams R. Improved outcome of paracetamol-induced fulminant hepatic failure by late administration of acetylcysteine. Lancet. 1990; 335 1572-1573
- 21 Donaldson B W, Gopinath R, Wanless I R et al.. The role of transjugular liver biopsy in fulminant liver failure: relation to other prognostic indicators. Hepatology. 1993; 18 1370-1376
- 22 Chung P Y, Sitrin M D, Te H S. Serum phosphorus levels predict clinical outcome in fulminant hepatic failure. Liver Transpl. 2003; 9 248-253
- 23 Schmidt L E, Dalhoff K. Alpha-fetoprotein is a predictor of outcome in acetaminophen-induced liver injury. Hepatology. 2005; 41 26-31
- 24 Baquerizo A, Anselmo D, Shackleton C et al.. Phosphorus as an early predictive factor in patients with acute liver failure. Transplantation. 2003; 75 2007-2014
- 25 Shami V M, Caldwell S H, Hespenheide E E, Arseneau K O, Bickston S J, Macik B G. Recombinant activated factor VII for coagulopathy in fulminant hepatic failure compared with conventional therapy. Liver Transpl. 2003; 9 138-143
- 26 Bernal W. Intensive care support therapy. Liver Transpl. 2003; 9(suppl 9) S15-S17
- 27 Vaquero J, Chung C, Cahill M E, Blei A T. Pathogenesis of hepatic encephalopathy in acute liver failure. Semin Liver Dis. 2003; 23 259-269
- 28 Vaquero J, Blei A T. Etiology and management of fulminant hepatic failure. Curr Gastroenterol Rep. 2003; 5 39-47
- 29 Wijdicks E F, Nyberg S L. Propofol to control intracranial pressure in fulminant hepatic failure. Transplant Proc. 2002; 34 1220-1222
- 30 Steinberg K P. Stress-related mucosal disease in the critically ill patient: risk factors and strategies to prevent stress-related bleeding in the intensive care unit. Crit Care Med. 2002; 30(Suppl 6) S362-S364
- 31 Jalan R. Intracranial hypertension in acute liver failure: pathophysiological basis of rational management. Semin Liver Dis. 2003; 23 271-282
- 32 Ellis A, Wendon J. Circulatory, respiratory, cerebral, and renal derangements in acute liver failure: pathophysiology and management. Semin Liver Dis. 1996; 16 379-388
- 33 Trewby P N, Williams R. Pathophysiology of hypotension in patients with fulminant hepatic failure. Gut. 1977; 18 1021-1026
- 34 Rolando N, Wade J, Davalos M, Wendon J, Philpott-Howard J, Williams R. The systemic inflammatory response syndrome in acute liver failure. Hepatology. 2000; 32(4 Pt 1) 734-739
- 35 Bouachour G, Tirot P, Varache N, Gouello J P, Harry P, Alquier P. Hemodynamic changes in acute adrenal insufficiency. Intensive Care Med. 1994; 20 138-141
- 36 Bollaert P E, Charpentier C, Levy B, Debouverie M, Audibert G, Larcan A. Reversal of late septic shock with supraphysiologic doses of hydrocortisone. Crit Care Med. 1998; 26 645-650
- 37 McCashland T M, Shaw Jr B W, Tape E. The American experience with transplantation for acute liver failure. Semin Liver Dis. 1996; 16 427-433
- 38 Davies M H, Mutimer D, Lowes J, Elias E, Neuberger J. Recovery despite impaired cerebral perfusion in fulminant hepatic failure. Lancet. 1994; 343 1329-1330
- 39 Wyke R J, Yousif-Kadaru A G, Rajkovic I A, Eddleston A L, Williams R. Serum stimulatory activity and polymorphonuclear leucocyte movement in patients with fulminant hepatic failure. Clin Exp Immunol. 1982; 50 442-449
- 40 Wyke R J, Rajkovic I A, Eddleston A L, Williams R. Defective opsonisation and complement deficiency in serum from patients with fulminant hepatic failure. Gut. 1980; 21 643-649
- 41 Altin M, Hughes R D, Williams R. Neutrophil adherence during hemoperfusion in fulminant hepatic failure. Int J Artif Organs. 1982; 5 315-317
- 42 Clapperton M, Rolando N, Sandoval L, Davies E, Williams R. Neutrophil superoxide and hydrogen peroxide production in patients with acute liver failure. Eur J Clin Invest. 1997; 27 164-168
- 43 Rolando N, Harvey F, Brahm J et al.. Prospective study of bacterial infection in acute liver failure: an analysis of fifty patients. Hepatology. 1990; 11 49-53
- 44 Rolando N, Philpott-Howard J, Williams R. Bacterial and fungal infection in acute liver failure. Semin Liver Dis. 1996; 16 389-402
- 45 Wade J, Rolando N, Philpott-Howard J, Wendon J. Timing and aetiology of bacterial infections in a liver intensive care unit. J Hosp Infect. 2003; 53 144-146
- 46 Rolando N, Gimson A, Wade J, Philpott-Howard J, Casewell M, Williams R. Prospective controlled trial of selective parenteral and enteral antimicrobial regimen in fulminant liver failure. Hepatology. 1993; 17 196-201
- 47 Salmeron J M, Tito L, Rimola A et al.. Selective intestinal decontamination in the prevention of bacterial infection in patients with acute liver failure. J Hepatol. 1992; 14 280-285
- 48 Rolando N, Wade J J, Stangou A et al.. Prospective study comparing the efficacy of prophylactic parenteral antimicrobials, with or without enteral decontamination, in patients with acute liver failure. Liver Transpl Surg. 1996; 2 8-13
- 49 Vaquero J, Polson J, Chung C et al.. Infection and the progression of hepatic encephalopathy in acute liver failure. Gastroenterology. 2003; 125 755-764
- 50 Billiau A, Vandekerckhove F. Cytokines and their interactions with other inflammatory mediators in the pathogenesis of sepsis and septic shock. Eur J Clin Invest. 1991; 21 559-573
- 51 Jalan R, Pollok A, Shah S H, Madhavan K, Simpson K J. Liver derived pro-inflammatory cytokines may be important in producing intracranial hypertension in acute liver failure. J Hepatol. 2002; 37 536-538
- 52 Bihari D J, Gimson A E, Williams R. Cardiovascular, pulmonary and renal complications of fulminant hepatic failure. Semin Liver Dis. 1986; 6 119-128
- 53 Briegel J, Forst H, Haller M et al.. Stress doses of hydrocortisone reverse hyperdynamic septic shock: a prospective, randomized, double-blind, single-center study. Crit Care Med. 1999; 27 723-732
- 54 Harry R, Auzinger G, Wendon J. The clinical importance of adrenal insufficiency in acute hepatic dysfunction. Hepatology. 2002; 36 395-402
- 55 Davenport A, Will E J, Davison A M et al.. Changes in intracranial pressure during haemofiltration in oliguric patients with grade IV hepatic encephalopathy. Nephron. 1989; 53 142-146
- 56 Davenport A, Will E J, Davidson A M. Improved cardiovascular stability during continuous modes of renal replacement therapy in critically ill patients with acute hepatic and renal failure. Crit Care Med. 1993; 21 328-338
- 57 Davenport A, Will E J, Davison A M. Continuous vs. intermittent forms of haemofiltration and/or dialysis in the management of acute renal failure in patients with defective cerebral autoregulation at risk of cerebral oedema. Contrib Nephrol. 1991; 93 225-233
- 58 O'Grady J G. Paracetamol hepatotoxicity: how to prevent. J R Soc Med. 1997; 90 368-370
- 59 Blei A T. Hypothermia for hypertension. Lancet. 1999; (9195) 2082
- 60 Clemmesen J O, Larsen F S, Kondrup J, Hansen B A, Ott P. Cerebral herniation in patients with acute liver failure is correlated with arterial ammonia concentration. Hepatology. 1999; 29 648-653
- 61 Strauss G I, Knudsen G M, Kondrup J, Moller K, Larsen F S. Cerebral metabolism of ammonia and amino acids in patients with fulminant hepatic failure. Gastroenterology. 2001; 121 1109-1119
- 62 Strauss G I, Christiansen M, Moller K, Clemmesen J O, Larsen F S, Knudsen G M. S-100b and neuron-specific enolase in patients with fulminant hepatic failure. Liver Transpl. 2001; 7 964-970
- 63 Keays R T, Alexander G J, Williams R. The safety and value of extradural intracranial pressure monitors in fulminant hepatic failure. J Hepatol. 1993; 18 205-209
- 64 Lidofsky S D, Bass N M, Prager M C et al.. Intracranial pressure monitoring and liver transplantation for fulminant hepatic failure. Hepatology. 1992; 16 1-7
- 65 Donovan J P, Shaw Jr B W, Langnas A N, Sorrell M F. Brain water and acute liver failure: the emerging role of intracranial pressure monitoring. Hepatology. 1992; 16 267-268
- 66 Larsen F S, Knudsen G M, Hansen B A. Pathophysiological changes in cerebral circulation, oxidative metabolism and blood-brain barrier in patients with acute liver failure: tailored cerebral oxygen utilization. J Hepatol. 1997; 27 231-238
- 67 Toftengi F, Larsen F S. Management of patients with fulminant hepatic failure and brain edema. Metab Brain Dis. 2004; 19 207-214
- 68 Blei A T, Olafsson S, Webster S, Levy R. Complications of intracranial pressure monitoring in fulminant hepatic failure. Lancet. 1993; 341 157-158
- 69 Vaquero J, Blei A, Fontana R J et al.. Complications and use of intracranial pressure monitoring in patients with acute liver failure and severe encephalopathy. Liver Transpl. 2005; 12 1581-1589
- 70 Cordoba J, Blei A T. Cerebral edema and intracranial pressure monitoring. Liver Transpl Surg. 1995; 1 187-194
- 71 Caldwell S H, Chang C, Macik B G. Recombinant activated factor VII (rFVIIa) as a hemostatic agent in liver disease: a break from convention in need of controlled trials. Hepatology. 2004; 39 592-598
- 72 Murphy N, Auzinger G, Bernel W, Wendon J. The effect of hypertonic sodium chloride on intracranial pressure in patients with acute liver failure. Hepatology. 2004; 39 464-470
- 73 Clemmesen J O, Kondrup J, Nielsen L B, Larsen F S, Ott P. Effects of high-volume plasmapheresis on ammonia, urea, and amino acids in patients with acute liver failure. Am J Gastroenterol. 2001; 96 1217-1223
- 74 Awad S S, Swaniker F, Magee J, Punch J, Bartlett R H. Results of a phase I trial evaluating a liver support device utilizing albumin dialysis. Surgery. 2001; 130 354-362
- 75 Rose C, Michalak A, Rao K V, Quack G, Kircheis G, Butterworth R F. L-ornithine-L-aspartate lowers plasma and cerebrospinal fluid ammonia and prevents brain edema in rats with acute liver failure. Hepatology. 1999; 30 636-640
- 76 Canalese J, Gimson A E, Davis C, Mellon P J, Davis M, Williams R. Controlled trial of dexamethasone and mannitol for the cerebral oedema of fulminant hepatic failure. Gut. 1982; 23 625-629
- 77 Ede R J, Gimson A E, Bihari D, Williams R. Controlled hyperventilation in the prevention of cerebral oedema in fulminant hepatic failure. J Hepatol. 1986; 2 43-51
- 78 Strauss G I, Moller K, Holm S, Sperling B, Knudsen G M, Larsen F S. Transcranial Doppler sonography and internal jugular bulb saturation during hyperventilation in patients with fulminant hepatic failure. Liver Transpl. 2001; 7 352-358
- 79 Strauss G, Hansen B A, Knudsen G M, Larsen F S. Hyperventilation restores cerebral blood flow autoregulation in patients with acute liver failure. J Hepatol. 1998; 28 199-203
- 80 Jensen K, Ohrstrom J, Cold G E, Astrup J. Indomethacin (Confortid) in severe head injury and elevated intracranial pressure (ICP). Acta Neurochir Suppl (Wien). 1992; 55 47-48
- 81 Chung C, Gottstein J, Blei A T. Indomethacin prevents the development of experimental ammonia-induced brain edema in rats after portacaval anastomosis. Hepatology. 2001; 34 249-254
- 82 Tofteng F, Larsen F S. The effect of indomethacin on intracranial pressure, cerebral perfusion and extracellular lactate and glutamate concentrations in patients with fulminant hepatic failure. J Cereb Blood Flow Metab. 2004; 24 798-804
- 83 Forbes A, Alexander G J, O'Grady J G et al.. Thiopental infusion in the treatment of intracranial hypertension complicating fulminant hepatic failure. Hepatology. 1989; 10 306-310
- 84 Peignoux M, Bernuau J, Benhamou J P. Total hepatectomy and hepatic vascular exclusion in the rat: a comparison, with special reference to the influence of body temperature. Clin Sci (Lond). 1982; 62 273-277
- 85 Eguchi S, Kamlot A, Ljubimova J et al.. Fulminant hepatic failure in rats: survival and effect on blood chemistry and liver regeneration. Hepatology. 1996; 24 1452-1459
- 86 Jalan R, Damink S W, Deutz N E, Lee A, Hayes P C. Moderate hypothermia for uncontrolled intracranial hypertension in acute liver failure. Lancet. 1999; 354 1164-1168
- 87 Jalan R, Olde Damink S W, Deutz N E et al.. Moderate hypothermia prevents cerebral hyperemia and increase in intracranial pressure in patients undergoing liver transplantation for acute liver failure. Transplantation. 2003; 75 2034-2039
- 88 Jalan R, Olde Damink S W, Deutz N E, Hayes P C, Lee A. Moderate hypothermia in patients with acute liver failure and uncontrolled intracranial hypertension. Gastroenterology. 2004; 127 1338-1346
- 89 Bernuau J. Acute liver failure: avoidance of deleterious cofactors and early specific medical therapy for the liver are better than late intensive care for the brain. J Hepatol. 2004; 41 152-155
- 90 Munoz S J. Hypothermia may impair hepatic regeneration in acute liver failure. Gastroenterology. 2005; 128 1143-1144 author reply 1144-1145
- 91 Rozga J, Williams F, Ro M S et al.. Development of a bioartificial liver: properties and function of a hollow-fiber module inoculated with liver cells. Hepatology. 1993; 17 258-265
- 92 Sussman N L, Kelly J H. Extracorporeal liver support: cell-based therapy for the failing liver. Am J Kidney Dis. 1997; 30(5, Suppl 4) S66-S71
- 93 Demetriou A A, Brown Jr R S, Busuttil R W et al.. Prospective, randomized, multicenter, controlled trial of a bioartificial liver in treating acute liver failure. Ann Surg. 2004; 239 660-667 discussion 667-670
- 94 Ellis A J, Hughes R D, Wendon J A et al.. Pilot-controlled trial of the extracorporeal liver assist device in acute liver failure. Hepatology. 1996; 24 1446-1451
- 95 Jalan R, Sen S, Williams R. Prospects for extracorporeal liver support. Gut. 2004; 53 890-898
- 96 Stange J, Mitzner S, Ramlow W, Gliesche T, Hickstein H, Schmidt R. A new procedure for the removal of protein bound drugs and toxins. ASAIO J. 1993; 39 M621-M625
- 97 Stange J, Ramlow W, Mitzner S, Schmidt R, Klinkmann H. Dialysis against a recycled albumin solution enables the removal of albumin-bound toxins. Artif Organs. 1993; 17 809-813
- 98 Stange J, Mitzner S R, Klammt S et al.. Liver support by extracorporeal blood purification: a clinical observation. Liver Transpl. 2000; 6 603-613
- 99 Lutkes P, Lutz J, Loock J et al.. Continuous venovenous hemodialysis treatment in critically ill patients after liver transplantation. Kidney Int Suppl. 1999; (72) S71-S74
- 100 Mitzner S R, Stange J, Klammt S et al.. Improvement of hepatorenal syndrome with extracorporeal albumin dialysis MARS: results of a prospective, randomized, controlled clinical trial. Liver Transpl. 2000; 6 277-286
- 101 Khuroo M S, Farahat K L. Molecular adsorbent recirculating system for acute and acute-on-chronic liver failure: a meta-analysis. Liver Transpl. 2004; 10 1099-1106
- 102 Sen S SC, Williams R.
Artificial liver support: overview of registry and controlled trials . In: Arroyo VFX, Garcia-Pagan JC Progress in the Treatment of Liver Diseases. Barcelona; Ars Medica 2003: 429-435MissingFormLabel - 103 Singh N, Gayowski T, Wagener M M, Marino I R. Outcome of patients with cirrhosis requiring intensive care unit support: prospective assessment of predictors of mortality. J Gastroenterol. 1998; 33 73-79
- 104 Kress J P, Rubin A, Pohlman A S, Hall J B. Outcomes of critically ill patients denied consideration for liver transplantation. Am J Respir Crit Care Med. 2000; 162(2 Pt 1) 418-423
- 105 Zimmerman J E, Wagner D P, Seneff M G, Becker R B, Sun X, Knaus W A. Intensive care unit admissions with cirrhosis: risk-stratifying patient groups and predicting individual survival. Hepatology. 1996; 23 1393-1401
- 106 Aggarwal A, Ong J P, Younossi Z M, Nelson D R, Hoffman-Hogg L, Arroliga A C. Predictors of mortality and resource utilization in cirrhotic patients admitted to the medical ICU. Chest. 2001; 119 1489-1497
- 107 Schrier R W, Arroyo V, Bernardi M, Epstein M, Henriksen J H, Rodes J. Peripheral arterial vasodilation hypothesis: a proposal for the initiation of renal sodium and water retention in cirrhosis. Hepatology. 1988; 8 1151-1157
- 108 Gores G J, Wiesner R H, Dickson E R, Zinsmeister A R, Jorgensen R A, Langworthy A. Prospective evaluation of esophageal varices in primary biliary cirrhosis: development, natural history, and influence on survival. Gastroenterology. 1989; 96 1552-1559
- 109 Groszmann R J, Bosch J, Grace N D et al.. Hemodynamic events in a prospective randomized trial of propranolol versus placebo in the prevention of a first variceal hemorrhage. Gastroenterology. 1990; 99 1401-1407
- 110 The North Italian Endoscopic Club for the Study and Treatment of Esophageal Varices. Prediction of the first variceal hemorrhage in patients with cirrhosis of the liver and esophageal varices: a prospective multicenter study. N Engl J Med. 1988; 319 983-989
- 111 Mahl T C, Groszmann R J. Pathophysiology of portal hypertension and variceal bleeding. Surg Clin North Am. 1990; 70 251-266
- 112 Garcia-Tsao G, Groszmann R J, Fisher R L, Conn H O, Atterbury C E, Glickman M. Portal pressure, presence of gastroesophageal varices and variceal bleeding. Hepatology. 1985; 5 419-424
- 113 Vorobioff J, Groszmann R J, Picabea E et al.. Prognostic value of hepatic venous pressure gradient measurements in alcoholic cirrhosis: a 10-year prospective study. Gastroenterology. 1996; 111 701-709
- 114 Moitinho E, Escorsell A, Bandi J C et al.. Prognostic value of early measurements of portal pressure in acute variceal bleeding. Gastroenterology. 1999; 117 626-631
- 115 Grace N D, Groszmann R J, Garcia-Tsao G et al.. Portal hypertension and variceal bleeding: an AASLD single topic symposium. Hepatology. 1998; 28 868-880
- 116 Rossle M. Prevention of rebleeding from oesophageal-gastric varices. Eur J Gastroenterol Hepatol. 2001; 13 343-348
- 117 Escorsell A, Bordas J M, Castaneda B et al.. Predictive value of the variceal pressure response to continued pharmacological therapy in patients with cirrhosis and portal hypertension. Hepatology. 2000; 31 1061-1067
- 118 Chalasani N, Kahi C, Francois F et al.. Improved patient survival after acute variceal bleeding: a multicenter, cohort study. Am J Gastroenterol. 2003; 98 653-659
- 119 Benoit J N, Womack W A, Korthuis R J, Wilborn W H, Granger D N. Chronic portal hypertension: effects on gastrointestinal blood flow distribution. Am J Physiol. 1986; 250(4 Pt 1) G535-G539
- 120 Graham D Y, Smith J L. The course of patients after variceal hemorrhage. Gastroenterology. 1981; 80 800-809
- 121 Kravetz D, Bosch J, Arderiu M, Pilar Pizcueta M, Rodes J. Hemodynamic effects of blood volume restitution following a hemorrhage in rats with portal hypertension due to cirrhosis of the liver: influence of the extent of portal-systemic shunting. Hepatology. 1989; 9 808-814
- 122 Kruskall M S, Mintz P D, Bergin J J et al.. Transfusion therapy in emergency medicine. Ann Emerg Med. 1988; 17 327-335
- 123 D'Amico G, De Franchis R. Upper digestive bleeding in cirrhosis: posttherapeutic outcome and prognostic indicators. Hepatology. 2003; 38 599-612
- 124 El-Serag H B, Everhart J E. Improved survival after variceal hemorrhage over an 11-year period in the Department of Veterans Affairs. Am J Gastroenterol. 2000; 95 3566-3573
- 125 Ioannou G N, Doust J, Rockey D C. Systematic review: terlipressin in acute oesophageal variceal haemorrhage. Aliment Pharmacol Ther. 2003; 17 53-64
- 126 Escorsell A, Ruiz del Arbol L, Planas R et al.. Multicenter randomized controlled trial of terlipressin versus sclerotherapy in the treatment of acute variceal bleeding: the TEST study. Hepatology. 2000; 32 471-476
- 127 Watanabe K, Kimura K, Matsutani S, Ohto M, Okuda K. Portal hemodynamics in patients with gastric varices: a study in 230 patients with esophageal and/or gastric varices using portal vein catheterization. Gastroenterology. 1988; 95 434-440
- 128 Sarin S K, Lahoti D, Saxena S P, Murthy N S, Makwana U K. Prevalence, classification and natural history of gastric varices: a long-term follow-up study in 568 portal hypertension patients. Hepatology. 1992; 16 1343-1349
- 129 Kim T, Shijo H, Kokawa H et al.. Risk factors for hemorrhage from gastric fundal varices. Hepatology. 1997; 25 307-312
- 130 Ohnishi K, Sato S, Saito M et al.. Clinical and portal hemodynamic features in cirrhotic patients having a large spontaneous splenorenal and/or gastrorenal shunt. Am J Gastroenterol. 1986; 81 450-455
- 131 Rinella M E, Shah D, Vogelzang R L, Blei A T, Flamm S L. Fundal variceal bleeding after correction of portal hypertension in patients with cirrhosis. Gastrointest Endosc. 2003; 58 122-127
- 132 Thakeb F, Salem S A, Abdallah M, el Batanouny M. Endoscopic diagnosis of gastric varices. Endoscopy. 1994; 26 287-291
- 133 Sarin S K, Govil A, Jain A K et al.. Prospective randomized trial of endoscopic sclerotherapy versus variceal band ligation for esophageal varices: influence on gastropathy, gastric varices and variceal recurrence. J Hepatol. 1997; 26 826-832
- 134 Sarin S K, Jain A K, Jain M, Gupta R. A randomized controlled trial of cyanoacrylate versus alcohol injection in patients with isolated fundic varices. Am J Gastroenterol. 2002; 97 1010-1015
- 135 Lo G H, Lai K H, Cheng J S, Chen M H, Chiang H T. A prospective, randomized trial of butyl cyanoacrylate injection versus band ligation in the management of bleeding gastric varices. Hepatology. 2001; 33 1060-1064
- 136 Gallet B, Zemour G, Saudemont J P, Renard P, Hillion M L, Hiltgen M. Echocardiographic demonstration of intracardiac glue after endoscopic obturation of gastroesophageal varices. J Am Soc Echocardiogr. 1995; 8(5 Pt 1) 759-761
- 137 Rickman O B, Utz J P, Aughenbaugh G L, Gostout C J. Pulmonary embolization of 2-octyl cyanoacrylate after endoscopic injection therapy for gastric variceal bleeding. Mayo Clin Proc. 2004; 79 1455-1458
- 138 See A, Florent C, Lamy P, Levy V G, Bouvry M. Cerebrovascular accidents after endoscopic obturation of esophageal varices with isobutyl-2-cyanoacrylate in 2 patients. Gastroenterol Clin Biol. 1986; 10 604-607
- 139 Yang W L, Tripathi D, Therapondos G, Todd A, Hayes P C. Endoscopic use of human thrombin in bleeding gastric varices. Am J Gastroenterol. 2002; 97 1381-1385
- 140 Yoshida T, Harada T, Shigemitsu T, Takeo Y, Miyazaki S, Okita K. Endoscopic management of gastric varices using a detachable snare and simultaneous endoscopic sclerotherapy and O-ring ligation. J Gastroenterol Hepatol. 1999; 14 730-735
- 141 Yoshida T, Hayashi N, Suzumi N et al.. Endoscopic ligation of gastric varices using a detachable snare. Endoscopy. 1994; 26 502-505
- 142 Kanagawa H, Mima S, Kouyama H, Gotoh K, Uchida T, Okuda K. Treatment of gastric fundal varices by balloon-occluded retrograde transvenous obliteration. J Gastroenterol Hepatol. 1996; 11 51-58
- 143 Fukuda T, Hirota S, Sugimura K. Long-term results of balloon-occluded retrograde transvenous obliteration for the treatment of gastric varices and hepatic encephalopathy. J Vasc Interv Radiol. 2001; 12 327-336
- 144 Sanyal A J. The use and misuse of transjugular intrahepatic portasystemic shunts. Curr Gastroenterol Rep. 2000; 2 61-71
- 145 Chau T N, Patch D, Chan Y W, Nagral A, Dick R, Burroughs A K. “Salvage” transjugular intrahepatic portosystemic shunts: gastric fundal compared with esophageal variceal bleeding. Gastroenterology. 1998; 114 981-987
- 146 Henderson J M. Role of distal splenorenal shunt for long-term management of variceal bleeding. World J Surg. 1994; 18 205-210
- 147 Merli M, Salerno F, Riggio O et al.. Transjugular intrahepatic portosystemic shunt versus endoscopic sclerotherapy for the prevention of variceal bleeding in cirrhosis: a randomized multicenter trial. Gruppo Italiano Studio Trends Pharmacol Sci (G.I.S.T.) Hepatology. 1998; 27 48-53
- 148 Zhou J H, Liu C Y, Zhang R H, Wang H R, Liu K J. Effects of octreotide on gallbladder pressure and myoelectric activity of Oddi sphincter in rabbits. World J Gastroenterol. 1998; 4 238-241
- 149 Garcia N, Sanyal A J. Portal hypertensive gastropathy and gastric antral vascular ectasia. Curr Treat Options Gastroenterol. 2001; 4 163-171
- 150 Kamath P S, Lacerda M, Ahlquist D A, McKusick M A, Andrews J C, Nagorney D A. Gastric mucosal responses to intrahepatic portosystemic shunting in patients with cirrhosis. Gastroenterology. 2000; 118 905-911
- 151 Bosch J, Thabut D, Bendtsen F et al.. Recombinant factor VIIa for upper gastrointestinal bleeding in patients with cirrhosis: a randomized, double-blind trial. Gastroenterology. 2004; 127 1123-1130
- 152 Jenkins S A, Shields R, Davies M et al.. A multicentre randomised trial comparing octreotide and injection sclerotherapy in the management and outcome of acute variceal haemorrhage. Gut. 1997; 41 526-533
- 153 Escorsell A, Bandi J C, Andreu V et al.. Desensitization to the effects of intravenous octreotide in cirrhotic patients with portal hypertension. Gastroenterology. 2001; 120 161-169
- 154 Besson I, Ingrand P, Person B et al.. Sclerotherapy with or without octreotide for acute variceal bleeding. N Engl J Med. 1995; 333 555-560
- 155 Sung J J, Chung S C, Yung M Y et al.. Prospective randomised study of effect of octreotide on rebleeding from oesophageal varices after endoscopic ligation. Lancet. 1995; 346 1666-1669
- 156 Conn H O, Ramsby G R, Storer E H et al.. Intraarterial vasopressin in the treatment of upper gastrointestinal hemorrhage: a prospective, controlled clinical trial. Gastroenterology. 1975; 68 211-221
- 157 Bosch J, Groszmann R J, Garcia-Pagan J C et al.. Association of transdermal nitroglycerin to vasopressin infusion in the treatment of variceal hemorrhage: a placebo-controlled clinical trial. Hepatology. 1989; 10 962-968
- 158 Gimson A E, Westaby D, Hegarty J, Watson A, Williams R. A randomized trial of vasopressin and vasopressin plus nitroglycerin in the control of acute variceal hemorrhage. Hepatology. 1986; 6 410-413
- 159 Soderlund C, Magnusson I, Torngren S, Lundell L. Terlipressin (triglycyl-lysine vasopressin) controls acute bleeding oesophageal varices: a double-blind, randomized, placebo-controlled trial. Scand J Gastroenterol. 1990; 25 622-630
- 160 Garcia-Compean D, Blanc P, Bories J M et al.. Treatment of active gastroesophageal variceal bleeding with terlipressin or hemostatic balloon in patients with cirrhosis: a randomized controlled trial. Arch Med Res. 1997; 28 241-245
- 161 Laine L, Cook D. Endoscopic ligation compared with sclerotherapy for treatment of esophageal variceal bleeding: a meta-analysis. Ann Intern Med. 1995; 123 280-287
- 162 Stiegmann G V, Goff J S, Michaletz-Onody P A et al.. Endoscopic sclerotherapy as compared with endoscopic ligation for bleeding esophageal varices. N Engl J Med. 1992; 326 1527-1532
- 163 Sarin S K, Lamba G S, Kumar M, Misra A, Murthy N S. Comparison of endoscopic ligation and propranolol for the primary prevention of variceal bleeding. N Engl J Med. 1999; 340 988-993
- 164 Sarin S K, Guptan R K, Jain A K, Sundaram K R. A randomized controlled trial of endoscopic variceal band ligation for primary prophylaxis of variceal bleeding. Eur J Gastroenterol Hepatol. 1996; 8 337-342
- 165 Lay C S, Tsai Y T, Teg C Y et al.. Endoscopic variceal ligation in prophylaxis of first variceal bleeding in cirrhotic patients with high-risk esophageal varices. Hepatology. 1997; 25 1346-1350
- 166 Harry R, Wendon J. Management of variceal bleeding. Curr Opin Crit Care. 2002; 8 164-170
- 167 Chojkier M, Conn H O. Esophageal tamponade in the treatment of bleeding varices: a decadel progress report. Dig Dis Sci. 1980; 25 267-272
- 168 Sanyal A J, Freedman A M, Luketic V A et al.. The natural history of portal hypertension after transjugular intrahepatic portosystemic shunts. Gastroenterology. 1997; 112 889-898
- 169 Sanyal A J, Freedman A M, Luketic V A et al.. Transjugular intrahepatic portosystemic shunts for patients with active variceal hemorrhage unresponsive to sclerotherapy. Gastroenterology. 1996; 111 138-146
- 170 Bureau C, Garcia-Pagan J C, Otal P et al.. Improved clinical outcome using polytetrafluoroethylene-coated stents for Trends Pharmacol Sci: results of a randomized study. Gastroenterology. 2004; 126 469-475
- 171 Rossi P, Salvatori F M, Fanelli F et al.. Polytetrafluoroethylene-covered nitinol stent-graft for transjugular intrahepatic portosystemic shunt creation: 3-year experience. Radiology. 2004; 231 820-830
- 172 Ockenga J, Kroencke T J, Schuetz T et al.. Covered transjugular intrahepatic portosystemic stents maintain lower portal pressure and require fewer reinterventions than uncovered stents. Scand J Gastroenterol. 2004; 39 994-999
- 173 Marchesini G, Fabbri A, Bianchi G, Brizi M, Zoli M. Zinc supplementation and amino acid-nitrogen metabolism in patients with advanced cirrhosis. Hepatology. 1996; 23 1084-1092
- 174 Kjaergard L L, Liu J, Als-Nielsen B, Gluud C. Artificial and bioartificial support systems for acute and acute-on-chronic liver failure: a systematic review. JAMA. 2003; 289 217-222
- 175 Blei A T, Cordoba J. Hepatic encephalopathy. Am J Gastroenterol. 2001; 96 1968-1976
- 176 Madoff D C, Perez-Young I V, Wallace M J, Skolkin M D, Toombs B D. Management of Trends Pharmacol Sci-related refractory hepatic encephalopathy with reduced Wallgraft endoprostheses. J Vasc Interv Radiol. 2003; 14 369-374
- 177 Kerlan Jr R K, LaBerge J M, Baker E L et al.. Successful reversal of hepatic encephalopathy with intentional occlusion of transjugular intrahepatic portosystemic shunts. J Vasc Interv Radiol. 1995; 6 917-921
- 178 Shioyama Y, Matsueda K, Horihata K et al.. Post-Trends Pharmacol Sci hepatic encephalopathy treated by occlusion balloon-assisted retrograde embolization of a coexisting spontaneous splenorenal shunt. Cardiovasc Intervent Radiol. 1996; 19 53-55
- 179 Bernard B, Cadranel J F, Valla D, Escolano S, Jarlier V, Opolon P. Prognostic significance of bacterial infection in bleeding cirrhotic patients: a prospective study. Gastroenterology. 1995; 108 1828-1834
- 180 Goulis J, Armonis A, Patch D, Sabin C, Greenslade L, Burroughs A K. Bacterial infection is independently associated with failure to control bleeding in cirrhotic patients with gastrointestinal hemorrhage. Hepatology. 1998; 27 1207-1212
- 181 Soriano G, Guarner C, Tomas A et al.. Norfloxacin prevents bacterial infection in cirrhotics with gastrointestinal hemorrhage. Gastroenterology. 1992; 103 1267-1272
- 182 Blaise M, Pateron D, Trinchet J C, Levacher S, Beaugrand M, Pourriat J L. Systemic antibiotic therapy prevents bacterial infection in cirrhotic patients with gastrointestinal hemorrhage. Hepatology. 1994; 20(1 Pt 1) 34-38
- 183 Hsieh W J, Lin H C, Hwang S J et al.. The effect of ciprofloxacin in the prevention of bacterial infection in patients with cirrhosis after upper gastrointestinal bleeding. Am J Gastroenterol. 1998; 93 962-966
- 184 Pauwels A, Mostefa-Kara N, Debenes B, Degoutte E, Levy V G. Systemic antibiotic prophylaxis after gastrointestinal hemorrhage in cirrhotic patients with a high risk of infection. Hepatology. 1996; 24 802-806
- 185 Bernard B, Grange J D, Khac E N, Amiot X, Opolon P, Poynard T. Antibiotic prophylaxis for the prevention of bacterial infections in cirrhotic patients with gastrointestinal bleeding: a meta-analysis. Hepatology. 1999; 29 1655-1661
- 186 Toledo C, Salmeron J M, Rimola A et al.. Spontaneous bacterial peritonitis in cirrhosis: predictive factors of infection resolution and survival in patients treated with cefotaxime. Hepatology. 1993; 17 251-257
- 187 Follo A, Llovet J M, Navasa M et al.. Renal impairment after spontaneous bacterial peritonitis in cirrhosis: incidence, clinical course, predictive factors and prognosis. Hepatology. 1994; 20 1495-1501
- 188 Navasa M, Follo A, Filella X et al.. Tumor necrosis factor and interleukin-6 in spontaneous bacterial peritonitis in cirrhosis: relationship with the development of renal impairment and mortality. Hepatology. 1998; 27 1227-1232
- 189 Garcia-Tsao G, Albillos A, Barden G E, West A B. Bacterial translocation in acute and chronic portal hypertension. Hepatology. 1993; 17 1081-1085
- 190 Llovet J M, Bartoli R, March F et al.. Translocated intestinal bacteria cause spontaneous bacterial peritonitis in cirrhotic rats: molecular epidemiologic evidence. J Hepatol. 1998; 28 307-313
- 191 Tito L, Rimola A, Gines P, Llach J, Arroyo V, Rodes J. Recurrence of spontaneous bacterial peritonitis in cirrhosis: frequency and predictive factors. Hepatology. 1988; 8 27-31
- 192 Andreu M, Sola R, Sitges-Serra A et al.. Risk factors for spontaneous bacterial peritonitis in cirrhotic patients with ascites. Gastroenterology. 1993; 104 1133-1138
- 193 Runyon B A. Low-protein-concentration ascitic fluid is predisposed to spontaneous bacterial peritonitis. Gastroenterology. 1986; 91 1343-1346
- 194 Conn H O. Spontaneous peritonitis and bacteremia in Laennec's cirrhosis caused by enteric organisms. A relatively common but rarely recognized syndrome. Ann Intern Med. 1964; 60 568-580
- 195 Guarner C, Soriano G. Spontaneous bacterial peritonitis. Semin Liver Dis. 1997; 17 203-217
- 196 McHutchison J, Runyon B A.
Spontaneous bacterial peritonitis . In: Surawicz CM, Owen R Gastrointestinal and Hepatic Infections. Philadelphia, PA; WB Saunders 1994: 455-475MissingFormLabel - 197 Runyon B A, Hoefs J C. Culture-negative neutrocytic ascites: a variant of spontaneous bacterial peritonitis. Hepatology. 1984; 4 1209-1211
- 198 Chu C M, Chang K Y, Liaw Y F. Prevalence and prognostic significance of bacterascites in cirrhosis with ascites. Dig Dis Sci. 1995; 40 561-565
- 199 Cabrera J, Arroyo V, Ballesta A M et al.. Aminoglycoside nephrotoxicity in cirrhosis: value of urinary beta 2-microglobulin to discriminate functional renal failure from acute tubular damage. Gastroenterology. 1982; 82 97-105
- 200 Felisart J, Rimola A, Arroyo V et al.. Cefotaxime is more effective than is ampicillin-tobramycin in cirrhotics with severe infections. Hepatology. 1985; 5 457-462
- 201 Runyon B A, McHutchison J G, Antillon M R, Akriviadis E A, Montano A A. Short-course versus long-course antibiotic treatment of spontaneous bacterial peritonitis: a randomized controlled study of 100 patients. Gastroenterology. 1991; 100 1737-1742
- 202 Sort P, Navasa M, Arroyo V et al.. Effect of intravenous albumin on renal impairment and mortality in patients with cirrhosis and spontaneous bacterial peritonitis. N Engl J Med. 1999; 341 403-409
- 203 Fernandez J, Monteagudo J, Bargallo X et al.. A randomized unblinded pilot study comparing albumin versus hydroxyethyl starch in spontaneous bacterial peritonitis. Hepatology. 2005; 42 627-634
- 204 Ochs A, Rossle M, Haag K et al.. The transjugular intrahepatic portosystemic stent-shunt procedure for refractory ascites. N Engl J Med. 1995; 332 1192-1197
- 205 Choudhury J, Sanyal A J. Treatment of ascites. Curr Treat Options Gastroenterol. 2003; 6 481-491
- 206 Luca A, Garcia-Pagan J C, Bosch J et al.. Beneficial effects of intravenous albumin infusion on the hemodynamic and humoral changes after total paracentesis. Hepatology. 1995; 22 753-758
- 207 Dagher L, Moore K. The hepatorenal syndrome. Gut. 2001; 49 729-737
- 208 Gines P, Cardenas A, Arroyo V, Rodes J. Management of cirrhosis and ascites. N Engl J Med. 2004; 350 1646-1654
- 209 Gines P, Guevara M, Arroyo V, Rodes J. Hepatorenal syndrome. Lancet. 2003; 362 1819-1827
- 210 Arroyo V, Gines P, Gerbes A L et al.. Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis. International Ascites Club. Hepatology. 1996; 23 164-176
- 211 Moller S, Bendtsen F, Henriksen J H. Pathophysiological basis of pharmacotherapy in the hepatorenal syndrome. Scand J Gastroenterol. 2005; 40 491-500
- 212 Laffi G, La Villa G, Gentilini P. Pathogenesis and management of the hepatorenal syndrome. Semin Liver Dis. 1994; 14 71-81
- 213 Arroyo V, Guevara M, Gines P. Hepatorenal syndrome in cirrhosis: pathogenesis and treatment. Gastroenterology. 2002; 122 1658-1676
- 214 Maurizio R, Eugenio C, Roberto P R. Results of sclerotherapy for bleeding esophageal varices in patients with schistosomal liver disease: a retrospective study. Hepatogastroenterology. 2000; 47 424-428
- 215 Ortega R, Gines P, Uriz J et al.. Terlipressin therapy with and without albumin for patients with hepatorenal syndrome: results of a prospective, nonrandomized study. Hepatology. 2002; 36(4 Pt 1) 941-948
- 216 Angeli P, Volpin R, Gerunda G et al.. Reversal of type 1 hepatorenal syndrome with the administration of midodrine and octreotide. Hepatology. 1999; 29 1690-1697
- 217 Wong F, Pantea L, Sniderman K. Midodrine, octreotide, albumin, and Trends Pharmacol Sci in selected patients with cirrhosis and type 1 hepatorenal syndrome. Hepatology. 2004; 40 55-64
- 218 Malinchoc M, Kamath P S, Gordon F D, Peine C J, Rank J, ter Borg P C. A model to predict poor survival in patients undergoing transjugular intrahepatic portosystemic shunts. Hepatology. 2000; 31 864-871
- 219 Wiesner R H, McDiarmid S V, Kamath P S et al.. MELD and PELD: application of survival models to liver allocation. Liver Transpl. 2001; 7 567-580
- 220 Wiesner R, Edwards E, Freeman R et al.. Model for end-stage liver disease (MELD) and allocation of donor livers. Gastroenterology. 2003; 124 91-96
Arun SanyalM.D.
Division of Gastroenterology, Department of Internal Medicine, Virginia Commonwealth
University
MCV Box 980341, Richmond, VA 23298-0341
Email: ajsanyal@hsc.vcu.edu